Standard of care for Lutetium (177Lu) Vipivotide Tetraxetan ("Pluvicto") therapy has been approved by Health Canada and is available within BC.
Please note, all documents on this webpage are provided for clinician-use only.
To initiate a Pluvicto referral for a patient:
1. Discuss and decide with patient the treatment and the implications (radiation, safety and travel) of proceeding with treatment
2. Complete a Compassionate Access Program (CAP) request form
- The BC Cancer Compassionate Access Program (CAP) is a secure online web-based system through which physicians across the province can submit requests, check the status of their requests, and receive notifications via email about the outcome.
- Please include all relevant details as described in this new CAP request
3. If the patient requires travel assistance (>200km from treatment center)
, complete the
Novartis Enrollment Form (attach to right hand
side of page) and fax it directly to Novartis Program at: 1-844-349-8758.
4. If the CAP request is approved:
5. If CAP request denied:
- Discuss alternatives with patient.
The BC Cancer Provincial Coordination Team will coordinate the handling of the referral with the treatment site who administers the treatment. The team will update the BC Cancer Provider via electronic medical record of the treatment dates and location once determined.
*If there are any tests supporting a referral or post treatment that are missing/outdated or required per protocol, it is the referring provider's responsibility to arrange for these tests.
For any questions, or to submit a referral, please contact: pluvictoreferrals@bccancer.bc.ca
Pluvicto Referral Form
Novartis Enrollment Form
Patient Information Sheet
UGUPLVT Protocol
The patient will receive a radiation safety information handout with detailed instructions from the site administering the Pluvicto therapy.
The handout will outline several radiation safety precautions to help reduce overall radiation exposure to the patient and others such as:
- Hydration in the days following treatment by drinking plenty of water. Urinate as much as possible (once an hour if you can) to help get rid of radiation in the body.
- Avoiding the use of public washrooms. Sit when using the toilet and flush twice.
- Transportation and accommodation recommendations following Pluvicto administration
- Limiting close contact with others (within 1-2 meters) after each dose for a specified period; longer from higher-risk groups such as children under 16 and pregnant people.
- Cleaning and/or disposing of materials that may encounter body fluids.
- Sexual activity restrictions include abstinence, use of condoms and sperm donation.
- A treatment card that the patient must carry during, and for 3 months following treatment, to present when receiving care in emergency or other health care setting.
Contact Information pluvictoreferrals@bccancer.bc.ca
